+

PE20020384A1 - PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C - Google Patents

PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C

Info

Publication number
PE20020384A1
PE20020384A1 PE2001000732A PE2001000732A PE20020384A1 PE 20020384 A1 PE20020384 A1 PE 20020384A1 PE 2001000732 A PE2001000732 A PE 2001000732A PE 2001000732 A PE2001000732 A PE 2001000732A PE 20020384 A1 PE20020384 A1 PE 20020384A1
Authority
PE
Peru
Prior art keywords
hepatitis
inhibitors
peptides
ns4a protease
virus
Prior art date
Application number
PE2001000732A
Other languages
English (en)
Inventor
Ashok Arasappan
Zhaoning Zhu
Stephane L Bogen
Tin-Yau Chan
Kevin X Chen
Ashit K Ganguly
Vyyoor Moopil Girijavallabhan
Siska Hendrata
Yushua Huang
Edwin E Jao
Scott Jeffrey Kemp
Odile Esther Levy
Marguerita Lim-Wilby
Yi-Tsung Liu
Raymond G Lovey
Jinping L Mccormick
George F Njoroge
Tejal N Parekh
Rusell E Pike
Patrick A Pinto
Anil K Saksena
Bama Santhanam
Susan Y Tamura
Henry A Vaccaro
Srikanth Venkatraman
Haiyan Wang
Wanli Wu
Frank Bennett
Original Assignee
Schering Corp
Dendreon Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22822136&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20020384(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, Dendreon Corp filed Critical Schering Corp
Publication of PE20020384A1 publication Critical patent/PE20020384A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/69—Benzenesulfonamido-pyrimidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A COMPUESTOS PEPTIDICOS QUE INCLUYEN ENANTIOMEROS, ESTEREOISOMEROS, ROTAMEROS, TAUTOMEROS, RACEMATOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C. SE REFIERE TAMBIEN A PROCEDIMIENTO PARA LA PREPARACION Y COMPOSICIONES FARMACEUTICAS UTILES PARA EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON LA PROTEASA SERINA NS3/NS4 DEL VIRUS DE LA HEPATITIS C
PE2001000732A 2000-07-21 2001-07-19 PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C PE20020384A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22011800P 2000-07-21 2000-07-21

Publications (1)

Publication Number Publication Date
PE20020384A1 true PE20020384A1 (es) 2002-05-28

Family

ID=22822136

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2001000732A PE20020384A1 (es) 2000-07-21 2001-07-19 PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C

Country Status (4)

Country Link
US (2) US6953802B2 (es)
AU (1) AU2001276022A1 (es)
PE (1) PE20020384A1 (es)
WO (1) WO2002008201A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
UY28391A1 (es) * 2003-06-25 2004-12-31 Elan Pharm Inc Metodos y composiciones para tratar artritis reumatoide
AR051984A1 (es) * 2004-12-08 2007-02-21 Bristol Myers Squibb Co Compuestos heterociclicos como inhibidores del factor viia
KR20080100271A (ko) 2006-02-27 2008-11-14 엘란 파마슈티칼스, 인크. Ｖｌａ-4에 의해 매개되는 백혈구 부착을 억제하는 피리미디닐 술폰아미드 화합물
US20080319652A1 (en) * 2007-06-20 2008-12-25 Radiofy Llc Navigation system and methods for map navigation
WO2011020874A1 (en) 2009-08-20 2011-02-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
WO2011133920A1 (en) 2010-04-23 2011-10-27 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
ES3003232T3 (en) 2018-10-30 2025-03-10 Gilead Sciences Inc Compounds for inhibition of alpha4beta7 integrin
JP7214882B2 (ja) 2018-10-30 2023-01-30 ギリアード サイエンシーズ， インコーポレイテッド アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
AU2019373240B2 (en) 2018-10-30 2023-04-20 Gilead Sciences, Inc. Quinoline derivatives as alpha4beta7 integrin inhibitors
ES2987796T3 (es) 2018-10-30 2024-11-18 Gilead Sciences Inc Derivados de N-benzoil-fenilalanina como inhibidores de la integrina alfa4beta7 para el tratamiento de enfermedades inflamatorias
EP4013499A1 (en) 2019-08-14 2022-06-22 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330506A3 (en) 1988-02-26 1990-06-20 Dana Farber Cancer Institute Vla proteins
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
JPH10506608A (ja) 1994-07-11 1998-06-30 アセナ ニューロサイエンシーズ，インコーポレイテッド 白血球接着のインヒビター

Also Published As

Publication number Publication date
WO2002008201A3 (en) 2002-06-27
US7223762B2 (en) 2007-05-29
US20050192280A1 (en) 2005-09-01
US20020058664A1 (en) 2002-05-16
AU2001276022A1 (en) 2002-02-05
WO2002008201A2 (en) 2002-01-31
US6953802B2 (en) 2005-10-11

Similar Documents

Publication Publication Date Title
EP1771454A4 (en) PEPTIDE ANALOGUE AS HEPATITIS C HEMMER
TW200615275A (en) Hepatitis C inhibitor dipeptide analogs
DE122012000004I1 (de) Peptide als inhibitoren der NS3-Serinprotease des hepatitis c virus.
PE20020384A1 (es) PEPTIDOS COMO INHIBIDORES DE LA PROTEASA SERINA NS3/NS4a DEL VIRUS DE LA HEPATITIS C
CL2012000919A1 (es) Composicion que comprende un compuesto derivado de metoxicarbonil-amino-metilbutanoil-pirrolidinil-imidazol de formula i, inhibidor especifico de ns5a de hcv, y un compuesto derivado de oxo-pirrolidin-quinoleina de formula ii, inhibidor de proteasa ns3 de hcv; y uso en el tratamiento de la hepatitis c.
NO20030271D0 (no) Nye peptider som NS3-serinproteaseinhibitorer for hepatitt C- virus
AR030591A1 (es) Inhibidores de proteasa peptidomimetica
GEP20104956B (en) Compounds for inhibiting hepatitis c viral replication and use thereof
UY28525A1 (es) Péptidos macrociclicos activos contra en virus de la hepatitis c
DOP2009000094A (es) Inhibidores de la proteasa ns3 del hcv
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
ATE486889T1 (de) Peptidanaloga mit inhibitorischer wirkung auf hepatitis c
IL176237A0 (en) Inhibitors of hepatitis c virus ns3/ns4a serine protease
ATE474827T1 (de) Hcv-replikationshemmer
UA83046C2 (ru) Соединения как ингибиторы вируса гепатита с, фармацевтическая композиция на их основе
DE60332814D1 (de) Peptide als hemmer der serinprotease des hepatitis c virus
HK1099028A1 (en) Substituted prolines as inhibitors of hepatitis c virus ns3 serine protease
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
PT1268519E (pt) Inibidores de serina protease, particularmente protease ns3 do virus da hepatite c
ATE497505T1 (de) Makrocyclische inhibitoren der ns3-serinprotease des hepatitis-c-virus
EA200900969A1 (ru) Макроциклические ингибиторы протеазы гепатита с
CR9731A (es) Inhibidores de proteasa ns3 del vhc
DE602005015093D1 (de) Neue verbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
TW200602037A (en) Novel compounds as inhibitors of hepatitis C virus NS3 serine protease
CL2012000054A1 (es) Composicion farmaceutica líquida que comprende a) un compuesto derivado de quinoleina-2,4,7,8-sustituida, inhibidor de la serina proteasa ns3 del virus de la hepatitis c (vhc), b) uno o mas lipidos, y c) uno o mas tensioactivos hidrofilos.

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载